Literature DB >> 30140845

Neuroscientifically Informed Formulation and Treatment Planning for Patients With Obsessive-Compulsive Disorder: A Review.

Darin D Dougherty1,2,3,4, Brian P Brennan2,4,5, S Evelyn Stewart6, Sabine Wilhelm3,4, Alik S Widge1,4,7, Scott L Rauch2,4.   

Abstract

Importance: Obsessive-compulsive disorder (OCD) is a common and often debilitating psychiatric illness. Recent advances in the understanding of the neuroscience of OCD have provided valuable insights that have begun to transform the way we think about the management of this disorder. This educational review provides an integrated neuroscience perspective on formulation and treatment planning for patients with OCD. The article is organized around key neuroscience themes most relevant for OCD. Observations: An integrated neuroscience formulation of OCD is predicated on a fundamental understanding of phenomenology and symptom dimensions, fear conditioning and extinction, neurochemistry, genetics and animal models, as well as neurocircuitry and neurotherapeutics. Symptom dimensions provide a means to better understand the phenotypic heterogeneity within OCD with an eye toward more personalized treatments. The concept of abnormal fear extinction is central to OCD and to the underlying therapeutic mechanism of exposure and response prevention. A framework for understanding the neurochemistry of OCD focuses on both traditional monoaminergic systems and more recent evidence of glutamatergic and γ-aminobutyric acid-ergic dysfunction. Obsessive-compulsive disorder is highly heritable, and future work is needed to understand the contribution of genes to underlying pathophysiology. A circuit dysregulation framework focuses on cortico-striato-thalamo-cortical circuit dysfunction and the development of neurotherapeutic approaches targeting this circuit. The impact of these concepts on how we think about OCD diagnosis and treatment is discussed. Suggestions for future investigations that have the potential to further enhance the clinical management of OCD are presented. Conclusions and Relevance: These key neuroscience themes collectively inform formulation and treatment planning for patients with OCD. The ultimate goal is to increase crosstalk between clinicians and researchers in an effort to facilitate translation of advances in neuroscience research to improved care for patients with OCD.

Entities:  

Mesh:

Year:  2018        PMID: 30140845     DOI: 10.1001/jamapsychiatry.2018.0930

Source DB:  PubMed          Journal:  JAMA Psychiatry        ISSN: 2168-622X            Impact factor:   21.596


  30 in total

1.  Towards a Clinically Valid Mechanistic Assessment of Exposure and Response Prevention: Preliminary Utility of an Exposure Learning Tool for Children with OCD.

Authors:  Jennie M Kuckertz; John Piacentini; Nader Amir
Journal:  J Obsessive Compuls Relat Disord       Date:  2020-03-23       Impact factor: 1.677

Review 2.  Obsessive-compulsive disorder.

Authors:  Dan J Stein; Daniel L C Costa; Christine Lochner; Euripedes C Miguel; Y C Janardhan Reddy; Roseli G Shavitt; Odile A van den Heuvel; H Blair Simpson
Journal:  Nat Rev Dis Primers       Date:  2019-08-01       Impact factor: 52.329

Review 3.  Pharmacotherapy for Treatment-Resistant Obsessive-Compulsive Disorder.

Authors:  Reilly R Kayser
Journal:  J Clin Psychiatry       Date:  2020-09-08       Impact factor: 4.384

4.  Cognitive performance in children and adolescents at high-risk for obsessive-compulsive disorder.

Authors:  Elisa Teixeira Bernardes; Leonardo Cardoso Saraiva; Marina de Marco E Souza; Marcelo Queiroz Hoexter; Priscila Chacon; Guaraci Requena; Euripedes Constantino Miguel; Roseli Gedanke Shavitt; Guilherme Vanoni Polanczyk; Carolina Cappi; Marcelo Camargo Batistuzzo
Journal:  BMC Psychiatry       Date:  2020-07-20       Impact factor: 3.630

5.  Acute effects of cannabinoids on symptoms of obsessive-compulsive disorder: A human laboratory study.

Authors:  Reilly R Kayser; Margaret Haney; Marissa Raskin; Caroline Arout; Helen Blair Simpson
Journal:  Depress Anxiety       Date:  2020-05-07       Impact factor: 6.505

Review 6.  Possible actions of cannabidiol in obsessive-compulsive disorder by targeting the WNT/β-catenin pathway.

Authors:  Alexandre Vallée; Yves Lecarpentier; Jean-Noël Vallée
Journal:  Mol Psychiatry       Date:  2021-04-09       Impact factor: 15.992

Review 7.  Toward a neurocircuit-based taxonomy to guide treatment of obsessive-compulsive disorder.

Authors:  Elizabeth Shephard; Emily R Stern; Odile A van den Heuvel; Daniel L C Costa; Marcelo C Batistuzzo; Priscilla B G Godoy; Antonio C Lopes; Andre R Brunoni; Marcelo Q Hoexter; Roseli G Shavitt; Y C Janardhan Reddy; Christine Lochner; Dan J Stein; H Blair Simpson; Euripedes C Miguel
Journal:  Mol Psychiatry       Date:  2021-01-07       Impact factor: 15.992

Review 8.  Efficacy and tolerability of repetitive transcranial magnetic stimulation for the treatment of obsessive-compulsive disorder in adults: a systematic review and network meta-analysis.

Authors:  Kaili Liang; Hailong Li; Xuan Bu; Xue Li; Lingxiao Cao; Jing Liu; Yingxue Gao; Bin Li; Changjian Qiu; Weijie Bao; Suming Zhang; Xinyu Hu; Haoyang Xing; Qiyong Gong; Xiaoqi Huang
Journal:  Transl Psychiatry       Date:  2021-05-28       Impact factor: 6.222

9.  Lost in translation: no effect of repeated optogenetic cortico-striatal stimulation on compulsivity in rats.

Authors:  Amanda R de Oliveira; Adriano E Reimer; Gregory J Simandl; Sumedh S Nagrale; Alik S Widge
Journal:  Transl Psychiatry       Date:  2021-05-24       Impact factor: 6.222

10.  Double blind randomized controlled trial of deep brain stimulation for obsessive-compulsive disorder: Clinical trial design.

Authors:  Nicole C R McLaughlin; Darin D Dougherty; Emad Eskandar; Herbert Ward; Kelly D Foote; Donald A Malone; Andre Machado; William Wong; Mark Sedrak; Wayne Goodman; Brian H Kopell; Fuad Issa; Donald C Shields; Osama A Abulseoud; Kendall Lee; Mark A Frye; Alik S Widge; Thilo Deckersbach; Michael S Okun; Dawn Bowers; Russell M Bauer; Dana Mason; Cynthia S Kubu; Ivan Bernstein; Kyle Lapidus; David L Rosenthal; Robert L Jenkins; Cynthia Read; Paul F Malloy; Stephen Salloway; David R Strong; Richard N Jones; Steven A Rasmussen; Benjamin D Greenberg
Journal:  Contemp Clin Trials Commun       Date:  2021-06-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.